Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jose R. Conejo-Garcia"'
Autor:
Jose R. Conejo-Garcia, Ahmad A. Tarhini, Savan Shah, William F. LaFramboise, Jamie K. Teer, Xiaoqing Yu, Maureen A. Lyons
Publikováno v:
Journal of Clinical Oncology. 39:e21584-e21584
e21584 Background: Predicting immune-related adverse events (irAEs) resulting from immune checkpoint inhibitors (ICIs) as well as the likelihood of clinical benefit is an area of great interest. irAEs have been associated with clinical outcome measur
Autor:
Andrea L. Buras, Robert M. Wenham, David Boulware, Jose R. Conejo-Garcia, Junmin Zhou, Alexandra Martin
Publikováno v:
Journal of Clinical Oncology. 39:e17538-e17538
e17538 Background: Despite evidence that ovarian cancer (OC) is an immunogenic disease, single-agent checkpoint inhibitors have shown limited response. A clinical trial was conducted evaluating dose-dense paclitaxel and pembrolizumab in platinum-resi
Autor:
Young-Chul Kim, Scott M. Gilbert, Wade J. Sexton, Michael A. Poch, Colin P.N. Dinney, Jasreman Dhillon, Jingsong Zhang, James J. Mulé, Rohit Jain, Roger Li, G.D. Grass, Anders Berglund, Jose R. Conejo-Garcia, Julio M. Pow-Sang, Logan Zemp, Shari Pilon-Thomas, Ryan Putney
Publikováno v:
Journal of Clinical Oncology. 39:466-466
466 Background: Adaptive anti-tumor immunity can be orchestrated by lymph node-like immune cell aggregates within the tumor microenvironment (TME) called tertiary lymphoid structures (TLSs). TLSs are postulated to be the gateway of lymphocyte infiltr
Autor:
Daniel C. Fernandez, Sachin M. Apte, Michael E. Montejo, Robert M. Wenham, Jose R. Conejo-Garcia, Kamran Ahmed, Hye Sook Chon, Mian M.K. Shahzad, Jing-Yi Chern, Cesar Lam, Sungjune Kim, Mitchel S. Hoffman, Young-Chul Kim
Publikováno v:
Journal of Clinical Oncology. 37:TPS5596-TPS5596
TPS5596 Background: There is no consistent recommendation for management of metastatic cervical cancer beyond first line therapy with chemotherapy and bevacizumab. Pembrolizumab is now approved for PD-L1 positive or MSI-H/dMMR metastatic or recurrent
Autor:
Carl H. June, Amy Ziober, Julia Tchou, Paul J. Zhang, Rena R. Xian, Yun Li, Jose R. Conejo-Garcia
Publikováno v:
Journal of Clinical Oncology. 32:11119-11119
11119 Background: Mesothelin, previously-shown to be expressed in triple negative breast cancer (TNBC) tumors, is a potential therapeutic target and prognostic marker in breast cancer. Methods: We ...